Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEG-rhG-CSF after Autologous HSCT for Lymphoma
NCT02905942Phase 4Unknown
- Sponsor
- Peking University
- Start
- Dec 2015
- Primary completion
- Dec 2018
- Modality
- Biologic, rProtein (Recombinant Protein)
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of pegfilgrastim in neutropenia (2 arms), sponsored by Peking University. Primary endpoint: Time to neutrophil engraftment at 30 days. Status: unknown.
02
Drugs
pegfilgrastim
03
Conditions
neutropenia
Beyond the preview
Go deeper on NCT02905942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02905942.